Our CEO Jeremy Skillington discusses Poolbeg Pharma, our strong cash position, high value programmes & multiple near-term value inflection points. 👉 POLB 001 - oral preventative therapy targeting cancer immunotherapy-induced CRS. 👉 Oral GLP-1 – targeting the growing obesity

Our Co-founder and Executive Chair Cathal Friel will be speaking at a panel discussion at the upcoming @_investorsummit event in London. 🗓️13 August 2025.🕒16:05 on Porter Tun Stage.🎙️The de-equitisation of Global Markets. Cathal will be joined by fellow panellists🗨️ David Belle

At Poolbeg Pharma we have identified a significant market opportunity in oncology for POLB 001 expected to exceed US$10 billion due to the rapid advancements in bispecific antibody and CAR T cell therapies. Currently, no therapies are approved for the prevention of Cytokine

Our CEO caught up with Joe Lynam at @NewstalkFM yesterday morning to discuss all things #POLB. 💥POLB 001 - potential to transform cancer care by making cancer immunotherapies safer & allowing their administration to move away from specialist cancer units and into the community.

A reminder that we are presenting this evening at the @MelloEventsUK Mello Monday webinar. 📅28 July from 6:10pm.🔵Speakers: Jeremy Skillington & Ian O'Connell.💻Virtual Presentation.Free Ticket Code: MMSHComp25. Register to attend:. #POLB #MelloMonday

We will be hosting a panel discussion at 3:05pm Investor Summit on Wednesday 13 August 2025 located at The Brewery, 52 Chiswell St, London, EC1Y 4SA. 🎤Panel discussion: Immunotherapy and the Future of Oncology: Breakthroughs, Barriers, and the Road Ahead. Panel Speakers 📢

Interesting article featured in @Nature Medicine on noncanonical and mortality-defining toxicities of CAR T cell therapy. Leading key opinion leaders in CAR T identify the need for new immunomodulators that can uncouple systemic cytokines from CAR T efficacy as a key research

Poolbeg Pharma is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. Our high value programmes target areas of high unmet medical need including cancer immunotherapy-induced Cytokine release Syndrome

Our Executive Chair Cathal Friel was featured in a @IrishTimes article on his journey as a serial entrepreneur, his unique approach to building public companies, and the philosophy that drives him. Cathal has created shareholder value by identifying undervalued opportunities,

Great to see the UK Government’s Life Sciences Sector Plan published, which looks to harness UK science and innovation, strengthen the NHS and drive long-term economic growth. The UK Government’s ambition is that the UK will be the leading life sciences economy in Europe by 2030

POLB 001 is a Phase 2-ready, orally-administered p38 MAP Kinase inhibitor designed to prevent cancer immunotherapy-induced CRS, a severe, potentially life-threatening side effect of cancer immunotherapies. Check out our overview:.✅Phase 2-ready oral small molecule.👉

FDA Orphan Drug Designation (ODD) brings many advantages including:. 👉 7 years of U.S. market exclusivity upon marketing authorisation with an additional 6 months paediatric exclusivity upon paediatric studies being submitted to the FDA. 👉 Waiver of NDA fees which are

Did you know the orphan drug market is expected to grow more than twice as fast as the non-orphan market?. 📈 Expected to grow from US$170bn in 2023 to US$368bn by 2030 (11.6% CAGR). 💊 Orphan drug sales set to account for 20% of all prescription drug sales by 2026. 💡POLB 001

We are presenting at the @MelloEventsUK webinar. 📅28 July at 5pm.🔵Speakers: CEO & CFO .💻Virtual Presentation. Register to attend:. #POLB #MelloMonday #VirtualPresentation

We featured in a @ShareTalkNews article titled “New Capital, New Catalysts as POLB 001 Advances Toward the Clinic”. 💪 Defining year backed by strong financial support.🚀 POLB 001 FDA Orphan Drug Designation.🔬 Upcoming POLB 001 & Oral GLP-1 clinical trials.👣 Strong IP and

Our CEO Jeremy Skillington was featured in a @TMSreach interview with @copytaster . ✅ Oversubscribed fundraise & next steps .💪 Big Pharma interest in POLB 001 .👉 Remaining on AIM .🔬 Upcoming key value inflection points .💰 Why buy in now?. Watch it here:

Our “laser-focused” efforts for the progression of POLB 001 was featured in a @businessposthq article. 👉Progressing clinical trial.🔬Interim results expected H1 2026.📈CRS major market opportunity.✅Orphan Drug Designation awarded by FDA.🚀Successful oversubscribed fundraise

Our Chief Executive Officer & Chief Financial Officer presented at last weeks’ @SHARESmag investor event in Manchester. If you were unable to attend the event, catch up on the recording shared below ⬇️. #POLB #Shares #SharesMagazine #AJBell

This week Poolbeg Pharma was featured in a @ShoreCapital Research Note ‘Poolbeg Primed to go’. 💰 Fundraising reflects pipeline ambitions.👑 POLB 001 the jewel in the crown.👉 Proof of concept for oral GLP-1 RA programme.✅ Important data points ahead. Access the note via